MANNKIND CORP Available-for-sale Securities, Gross Realized Gain (Loss)
MANNKIND CORP (MNKD) reported Available-for-sale Securities, Gross Realized Gain (Loss) of -$990.00 thousand for the 283-month period ending 2014-09-30, per its 10-Q filed 2014-11-10.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet · last filed 2015-03-02
- MANNKIND CORP available-for-sale securities, gross realized gain (loss) for the quarter ending 2012-12-31 was $0.00.
- MANNKIND CORP available-for-sale securities, gross realized gain (loss) for the quarter ending 2012-09-30 was $0.00.
- MANNKIND CORP available-for-sale securities, gross realized gain (loss) for the quarter ending 2012-06-30 was $0.00.
- MANNKIND CORP available-for-sale securities, gross realized gain (loss) for the quarter ending 2012-03-31 was -$117.00K.
- MANNKIND CORP available-for-sale securities, gross realized gain (loss) for fiscal 2012 was -$117.00K.
- MANNKIND CORP available-for-sale securities, gross realized gain (loss) for fiscal 2010 was -$644.00K.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss) 3 month | Available-for-sale Securities, Gross Realized Gain (Loss) 6 month | Available-for-sale Securities, Gross Realized Gain (Loss) 9 month | Available-for-sale Securities, Gross Realized Gain (Loss) 12 month | Available-for-sale Securities, Gross Realized Gain (Loss) 244 month | Available-for-sale Securities, Gross Realized Gain (Loss) 247 month | Available-for-sale Securities, Gross Realized Gain (Loss) 250 month | Available-for-sale Securities, Gross Realized Gain (Loss) 253 month | Available-for-sale Securities, Gross Realized Gain (Loss) 256 month | Available-for-sale Securities, Gross Realized Gain (Loss) 259 month | Available-for-sale Securities, Gross Realized Gain (Loss) 263 month | Available-for-sale Securities, Gross Realized Gain (Loss) 265 month | Available-for-sale Securities, Gross Realized Gain (Loss) 268 month | Available-for-sale Securities, Gross Realized Gain (Loss) 271 month | Available-for-sale Securities, Gross Realized Gain (Loss) 275 month | Available-for-sale Securities, Gross Realized Gain (Loss) 277 month | Available-for-sale Securities, Gross Realized Gain (Loss) 280 month | Available-for-sale Securities, Gross Realized Gain (Loss) 283 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-09-30 | -$990.00K 10-Q · filed 2014-11-10 | |||||||||||||||||
| 2014-06-30 | -$990.00K 10-Q · filed 2014-08-11 | |||||||||||||||||
| 2014-03-31 | -$990.00K 10-Q · filed 2014-05-12 | |||||||||||||||||
| 2013-12-31 | -$990.00K 10-K · filed 2014-03-03 | |||||||||||||||||
| 2013-09-30 | -$990.00K 10-Q · filed 2013-11-12 | |||||||||||||||||
| 2013-06-30 | -$990.00K 10-Q · filed 2013-08-09 | |||||||||||||||||
| 2013-03-31 | -$990.00K 10-Q · filed 2013-05-10 | |||||||||||||||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $0.00 derived: sum of 2 quarters · filed 2015-03-02 | $0.00 derived: sum of 3 quarters · filed 2015-03-02 | -$117.00K 10-K · filed 2015-03-02 | -$990.00K 10-K · filed 2013-03-18 | |||||||||||||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $0.00 derived: sum of 2 quarters · filed 2013-11-12 | -$117.00K 10-Q · filed 2013-11-12 | -$990.00K 10-Q · filed 2012-11-09 | ||||||||||||||
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$117.00K 10-Q · filed 2013-08-09 | -$990.00K 10-Q · filed 2012-08-09 | |||||||||||||||
| 2012-03-31 | -$117.00K 10-Q · filed 2013-05-10 | -$990.00K 10-Q · filed 2012-05-10 | ||||||||||||||||
| 2011-12-31 | -$873.00K 10-K · filed 2012-03-15 | |||||||||||||||||
| 2011-09-30 | -$873.00K 10-Q · filed 2011-11-04 | |||||||||||||||||
| 2011-06-30 | -$873.00K 10-Q · filed 2011-08-04 | |||||||||||||||||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | -$297.00K derived: sum of 2 quarters · filed 2013-03-18 | -$644.00K 10-K · filed 2013-03-18 | |||||||||||||||
| 2010-09-30 | -$297.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | -$644.00K 10-Q · filed 2011-11-04 | ||||||||||||||||
| 2010-06-30 | -$347.00K 10-Q · filed 2011-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |